| INTRODUC TI ON
In this short review, current clinical conundrums on von Willebrand disease (VWD) will be addressed. Despite more knowledge on the pathophysiology of VWD, improvement of diagnostic strategies and advances in clinical care for patients with VWD still several problems and dilemmas remain. In this review, the latest findings regarding the pathology, including controversial borders for definition of the disease, diagnostic dilemma when von Willebrand factor (VWF) levels evolve with age, laboratory issues rendering difficult the classification of the different types of VWD and the current principles of care, including prophylaxis, related to these issues will be addressed. In addition, the importance of the loss of high molecular weight (HMW) VWF multimers in a subset of patients with congenital or acquired von VWD, which can be associated with severe bleeding related to vascular malformations in the gastrointestinal tract or other tissues will be reviewed. Also, the therapeutic options that can be proposed for these severe and difficult to control bleeding episodes in patients with VWD will be discussed.
| D IAG NOS IS AND CL A SS IFI C ATI ON OF V WD
Von Willebrand disease is the most common autosomal inherited bleeding disorder, mainly characterized by mucocutaneous bleeding and is caused by reduced VWF activity. 1 Epidemiological studies have indicated that the prevalence of VWD is around 1%, however, far less individuals with reduced VWF activity have bleeding problems that require treatment. 2, 3 To make the diagnosis of VWD a well-structured bleeding history should be obtained from every individual patient. For this purpose, various bleeding scores have been developed and optimized in recent years. 4, 5 In addition, several laboratory test have to be performed, including VWF antigen (VWF:Ag) and VWF platelet-dependent activity, as measured by the ristocetin-cofactor activity (VWF:RCo), or VWF collagen-binding activity (VWF:CB). As FVIII is bound in circulation to VWF, thereby protecting FVIII from degradation, many patients with VWD also have reduced FVIII levels, which should therefore be determined in individuals suspected for VWD. In addition, VWF multimer analysis and more specific VWF tests are performed to further classify VWD into the various subtypes (see Ng et al 6 for a recent review 17, 18 In both the WiN and the Zimmermann study patients diagnosed with type 1 VWD in the past, who had VWF levels higher than 30 IU/dL at the time of inclusion in the study, had a significant bleeding phenotype and high bleeding scores. 18 These studies also found VWF gene mutations in around 40%-60% of individuals with mildly reduced VWF levels (low VWF), whereas these are found in 70%-95% of patients with VWD disease. 16, 18 should also be given to increase FVIII levels to a therapeutic level. 31 In elective situations, VWF concentrate can be given the day before the intervention, because endogenous FVIII levels rise to 60 IU/dL after 6 hours. 31 The advantage of the pure VWF concentrates is that they do not lead to strongly increased FVIII levels after several days of treatment, as this may lead to a higher risk of venous thrombosis. 32 Recently, recombinant VWF has become available in the USA for treatment of bleeding episodes in patients with severe VWD. 33 However, this is not yet available in many other countries.
| PROPHYL A XIS IN V WD
The phenotypic spectrum of VWD is strongly variable. Some patients with type 2 or type 3 VWD have a mild bleeding tendency, whereas others experience severe bleeding problems, such as joint bleeding or recurrent gastrointestinal bleeding (GIB). 34 Despite the use of prophylactic treatment with factor concentrates in haemophilia patients for many decades, prophylaxis is not frequently started in VWD patients with a severe bleeding phenotype and VWF concentrates are not even licensed for prophylaxis in many countries. 35 Although efficacy data are largely derived from case series, recently, some prospective studies have been performed to study the value of prophylaxis in patients with severe VWD. 36, 37 This is important because of the potential development of arthropathy in patients with VWD after joint bleeds, which is still under-recognized in these patients. 38, 39 Prophylaxis in selected patients with recurrent bleeding episodes reduced the bleeding rate in most individuals, including those with recurrent joint bleeds. 37, 40 Therefore, prophylaxis seems to be of benefit for selected patients with severe VWD. 41 A study on the use of regular prophylaxis with recombinant VWF concentrate is ongoing.
| VON WILLEB R AND AND THE VA SCUL AR MEMB R ANE
Gastrointestinal bleedings from angiodysplasias (ADs) are frequently observed in congenital VWD, but almost exclusively in patients lacking high-molecular-weight (HMW-) VWF multimers (Types 2A, 2B or 3). 42 It is established from in vitro and in vivo studies that VWF can regulate angiogenesis through multiple pathways, indicating that VWF may be involved in the pathogenesis of ADs beyond the control of hemostasis. 43 In VWD type 2A, mutations in VWF induce defects in multimerization, secretion, regulated storage or an increased degradation of multimers by ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats 13).
Interestingly, this increased incidence of GIB from ADs is not unique to congenital VWD and is also reported as "Heyde's syndrome" in several high shear cardiovascular disorders associated with an acquired loss of HMW-multimers, mostly aortic stenosis and mechanical circulatory support (MCS). 44 Despite improvements in pump's design translating in higher survival rates, GIB and epistaxis are a hallmark of both short-term (extracorporeal membrane oxygenation, ECMO) and long-term MCS (ventricular assist devices, VAD), with a high recurrence rate. Bleeding complications represent therefore a major clinical issue in these patients, as it is plaguing patient management, quality of life, costs and survival. 45, 46 Ultimately, severe bleeding may lead to the interruption of some of the antithrombotic medications, which is associated with an increased rate of thrombotic complications including stroke and pump thrombosis. 47 There is still some uncertainty about the mechanism(s) un- 
| THER APEUTI C OP TI ON S FOR B LEED ING EPISODE S REL ATED TO VA SCUL AR MALFORMATI ON S IN THE G A S TROINTE S TINAL TR AC T OR OTHER TISSUE S IN PATIENTS WITH V WD
In view of the "2-hit" model, several approaches might be useful to prevent and manage bleeding from AVMs: some aiming to prevent or to eradicate ADs and others aiming to prevent or reduce HMWmultimers defect.
In the setting of congenital or acquired VWD complicated by GIB, it is mandatory to rule out the presence of an active bleeding lesion accessible to endoscopic treatment. If conventional upper and lower endoscopy fails to identify the source of bleeding, a small bowel video capsule endoscopy should be performed to look after small bowel ADs in accordance to European guidelines. 57, 58 Indeed, some ADs might be eligible to endoscopic treatment during balloon enteroscopy using Argon plasma coagulation, bipolar electrocautery probes, endoclips or cryotherapy.
In patients with recurrent bleeds or in whom a lesion cannot be localized or treated by endoscopy, several pharmacological approaches might be discussed. In this setting, prophylactic replacement therapy using VWF concentrates can be used in congenital VWD and in acquired VWD associated with monoclonal gammopathy. However, GIB often requires frequent dosing and high dosages of VWF concentrates and rapid prophylaxis escalation which can compromise the patient's adherence to treatment. Indeed, prophylactic intravenous VWF infusions seem less effective to control GIB than other bleeding complications such as menorrhagia, hemarthrosis or epistaxis. 37 In the specific setting of MCS, there is currently no evidence supporting the use of VWF concentrates which might have limited efficacy due to the short half-life of VWF. However, the use of VWF concentrates has been reported in some cases. 59 Lowering antithrombotic therapy might be elected for severe bleedings but conveys the risk of subsequent stroke and pump's thrombosis. According to International Society for Heart and Lung Transplantation guidelines, lowering pump's speed to restore some degree of arterial pulsatility is another option in the case of recurrent GIBs from ADs. 60 In the setting of Heyde's syndrome associated with cardiac valvular diseases, the AVWS is reversed almost immediately upon surgical or transcatheter valvular replacement. 61 In case of refractory GIBs not eligible to endoscopic treatment and VWF replacement therapy, consideration may be given to antiangiogenic drugs such as thalidomide, octreotide or statin, although these drugs are not licensed for this indication. However, data surrounding their overall efficacy and safety in both congenital and acquired VWD are mostly based from case reports and small series. In MCS, it has recently been shown in a multicentric study that secondary prophylaxis with octreotide reduces the recurrences of GIBs. 62 In these challenging patients, the development of targeted drugs preventing HMW-multimers loss without increasing platelet adhesion and aggregation would be an attractive option. Doxycycline, an inexpensive and commonly prescribed tetracycline antibiotic, has been shown to inhibit proteolytic cleavage of VWF in the presence of LVAD-associated shear stress at plasma concentrations of 5-20 mg/dL, which are at least 10-fold higher than the usual standard dosing. 63 A monoclonal antibody anti-VWF D4 domain partially inhibiting VWF binding to ADAMTS13 was also reported to prevent endogenous HMW-multimers cleavage in a mock circulatory loop LVAD model. 64 
| CON CLUS IONS
Despite increasing knowledge and insights into the diagnosis, pathophysiology and management of VWD, still several issues and questions still remain. This accounts both inherited VWD as the AVWS associated with mechanical circulatory support. In this concise review, we have addressed several of the current clinical conundrums, but many more are to be discussed. In the Table 1 , we have mentioned some of these questions which may help to define areas for further research for the VWD research community to achieve improvement of the diagnostic approach of VWD and improved treatment for patients with VWD.
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R E FE R E N C E S
TA B L E 1 Clinical conundrums and remaining questions regarding the diagnosis and treatment of VWD Current clinical conundrums: diagnosis How do we distinguish individuals with low VWF levels, "low VWF" and VWD type 1?
Can we improve bleeding assessment tools to improve VWD diagnosis?
Is bleeding in "low VWF" patients caused by the low VWF levels or multifactorial?
Can we improve the classification of type 2 in the various subtypes?
How can we use genetic testing to better classify patients in type 1 or 2?
Should we use VWF:CB assay (and which assay) in the diagnosis of VWD?
Current clinical conundrums: Treatment
What are the target levels of VWF or FVIII during surgical interventions?
Can dosing be optimized using pharmacokinetic profiles?
Should we use platelet concentrates in bleeding VWD patients?
How can we improve the treatment of GI bleeding in VWD type 2 and 3 and AVWS?
Can we prevent bleeding problems in patients with mechanical circulatory support?
Is treatment of patients with "low VWF" necessary?
How do we manage elderly VWD type 1 patients with raised (normalized) VWF levels?
What is the optimal VWD prophylaxis scheme in severely bleeding VWD patients?
AVWS, acquired von Willebrand syndrome; VWD, von Willebrand disease, VWF, von Willebrand factor; VWF:CB, VWF collagen-binding activity.
